Peroxisome proliferator-activated receptor gamma (PPARγ) expression is decreased in pulmonary hypertension and affects endothelial cell growth

Circulation Research

Volumn 92, Issue 10, 2003, Pages 1162-1169

  Ameshima, Shingo ^a   Golpon, Heiko ^c   Cool, Carlyne D ^a   Chan, Daniel ^a   Vandivier, R William ^a,b   Gardai, Shyra J ^a,b   Wick, Marilee ^a   Nemenoff, Raphael A ^a   Geraci, Mark W ^a   Voelkel, Norbert F ^a,d  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c Pulmonary Division   (Germany)

^d Division of Pulmonary Sciences and Critical Care Medicine   (United States)

Author keywords

Apoptosis; Endothelial cell growth; Peroxisome proliferator activated receptor ; Severe pulmonary hypertension; Shear stress

Indexed keywords

MATRIGEL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SEMAXANIB;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIOLE; ARTICLE; CELL GROWTH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; MALE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHEAR STRESS; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION; GENES, DOMINANT; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRESS, MECHANICAL; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0038389113     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000073585.50092.14     Document Type: Article

References (49)

1. Mukherjee R, Jow L, Croston GE, Paterniti JR Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonist and antagonists. J Biol Chem. 1997;272:8071-8076.
2. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature. 1992;358:771-774.
3. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA. Peroxisome proliferator-activated receptor (PPAR)γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 1994;135:798-800.
4. Wu Z, Bucher NLR, Farmer SR. Induction of peroxisome proliferator-activated receptor y during the conversation of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPα, and glucocorticoids. Mol Cell Biol. 1996;16:4128-4136.
5. Michael LF, Lazar MA, Mendelson CR. Peroxisome proliferator-activated receptor γ1 expression is induced during cyclic adenosine monophosphate-stimulated differentiation of alveolar type II pneumonocytes. Endocrinology. 1997;138:3695-3703.
6. von Knethen A, Brune B. Delayed activation at PPARγ by LPS and INFγ attenuates the oxidative burst in macrophages. FASEB J. 2001;15:535-544.
7. Jiang C, Ting AT, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
8. Davies SS, Pontsler AV, Marathe GK, Harrison KA, Murphy RC, Hinshaw JC, Prestwich GD, Hilaire AS, Prescott SM, Zimmerman GA, McIntyre TM. Oxidized alkyl phospholipids are specific, high affinity PPARγ ligands and agonists. J Biol Chem. 2001;276:16015-23.
9. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1998;95:7614-7619.
10. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. Loss-of-function mutation in PPARγ associated with human colon cancer. Mol Cell. 1999;3:799-804.
11. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci USA. 2000;97:10990-10995.
12. Brockman JA, Gupta A, DuBois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology. 1998;115:1049-1055.
13. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, Sporn MB. A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999;59:5671-5673.
14. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocytes-derived macrophages. J Biol Chem. 1998;273:25573-25580.
15. 2. J Biol Chem. 1999;274:17042-17048.
16. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest. 2000;106:189-197.
17. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun. 2000;270:400-405.
18. Harris SG, Phipps RP. The nuclear receptor PPARγ is expressed by mouse T lymphocytes and PPARγ agonists induce apoptosis. Eur J Immunol. 2001;31:1098-105.
19. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999;274:13, 9116-9121.
20. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, Moses MA, Kilroy S, Duensing S, Fletcher C, Fletcher JA, Hlatky L, Hahnfeldt P, Folkman J, Kaipainen A. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110:923-932.
21. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70-75.
22. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-1932.
23. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol. 1999;155:411-419.
24. Tuder RM, Chacon M, Alger L, Wang J, Taraseviciene-Stewart L, Kasahara Y, Cool CD, Bishop AE, Geraci M, Semenza GL, Yacoub M, Polak JM, Voelkel NF. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of -disordered angiogenesis. J Pathol. 2001;195:367-374.
25. Golpon HA, Geraci MW, Moore MD, Miller HL, Miller GJ, Tuder RM, Voelkel NF. HOX genes in human lung: altered expression in primary pulmonary hypertension and emphysema. Am J Pathol. 2001;158:955-966.
26. Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF. 5-lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;157:219-229.
27. Geraci MW, Moore M, Gesell T, Yeager ME, Alger L, Golpon H, Gao B, Loyd JE, Tuder RM, Voelkel NF. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res. 2001;88:555-562.
28. Zakrzewicz A, Secomb TW, Pries AR. Angioadaptation, keeping the vascular system in shape. News Physiol Sci. 2002;17:197-201.
29. Takahashi K, Sawasaki Y, Hata J-I, Mukai K, Goto T. Spontaneous transformation and immortalization of human endothelial cells. In Vitro Cell Dev Biol. 1990;25:263-274.
30. Hughes SE. Functional characterization of the spontaneously transformed human umbilical vein endothelial cell line ECV304: use in an in vitro model of angiogenesis. Exp Cell Res. 1996;225:171-185.
31. Osanai T, Okada S, Sirato K, Nakano T, Saitoh M, Magota K, Okumura K. Mitochondrial coupling factor 6 is present on the surface of human vascular endothelial cells and is released by shear stress. Circulation. 2001;104:3132-3136.
32. Ding K, Sandgren S, Mani K, Belting M, Fransson LA. Modulations of glypican-1 heparan sulfate structure by inhibition of endogenous polyamine synthesis: mapping of spermine-binding sites and heparinase, heparin lyase, and nitric oxide/nitrite cleavage sites. J Biol Chem. 2001;276:46779-46791.
33. Gu Y, Xu Y, Wu RF, Souza RF, Nwariaku FE, Terada LS. TNFα activates c-Jun amino terminal kinase through p47 (phox). Exp Cell Res. 2002;272:62-74.
34. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001;15:427-438.
35. Landau NR, Littman DR. Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol. 1992;66:5110-5113.
36. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A. 1993;90:8392-8396.
37. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK. A dominant-negative peroxisome proliferatoractivated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J Biol Chem. 2000;275:5754-5759.
38. Yeager MR, Halley GR, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res. 2001;88:e2-e11.
39. Kersten S, Desvergne B, Wahli W. Role of PPARs in health and disease. Nature. 2000;405:421-424.
40. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001;163:737-744.
41. Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF Jr, Gimbron MA Jr. Platelet-derived growth factor B chain promoter contains a cisacting fluid shear-stress responsive element. Proc Natl Acad Sci USA. 1993;90:4591-4595.
42. Urbich C, Walter DH, Zeiher AM, Dimmeler S. Laminar shear stress upregulates integrin expression role in endothelial cell adhesion and apoptosis. Circ Res. 2000;87:683-689.
43. Bartling B, Tostlebe H, Darmer D, Holtz J, Silber RE, Morawietz H. Shear stress-dependent expression of apoptosis-regulating genes in endothelial cells. Biochem Biophys Res Commun. 2000;278:740-746.
44. 2-induced apoptosis of human endothelial cells by modulation of the glutathione redox cycle and nitric oxide synthase. Arterioscler Thromb Vasc Biol. 1997;17:3588-3592.
45. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001;108:1141-1150.
46. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 1998;98:1400-1406.
47. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6:698-702.
48. Rabinovitch M. Pathobiology of pulmonary hypertension: extracellular matrix. Clin Chest Med. 2001;22:433-449.
49. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension: the International PPH Consortium. Nat Genet. 2000;26:81-84.